+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Investigation Report on China's Simvastatin Market, 2019-2023

  • ID: 4752248
  • Report
  • February 2019
  • Region: China
  • 30 pages
  • China Research & Intelligence
1 of 5

FEATURED COMPANIES

The blood lipid levels of Chinese people are rising as China's economy develops and a high-calorie and high-fat diet becomes increasingly prevalent. In 2018, the overall incidence of dyslipidemia in Chinese adults was up to about 40%. As dyslipidemia is a major cause of coronary heart disease, strokes and other atherosclerotic lesions, the treatment of hyperlipidemia can reduce the incidence of these diseases.

Developed by U.S. company MSD, Simvastatin is a semi-synthetic HMG-CoA reductase inhibitor with Lovastatin as the raw material. It was first launched in 1988, and approved by the FDA in Dec. 1991. The trade name of MSD's Simvastatin is Zocor. Simvastatin can prevent the development of atherosclerosis and prevent the relapse of heart diseases, and reduce the risks of nonfatal myocardial infarction and myocardial revascularization.

In 1995, MSD introduced Simvastatin to China. Simvastatin is the first widely used statin in China and the only statin that has been included in China's essential medicine list and needs to complete the consistency evaluation by 2018. And the users of Simvastatin can enjoy some preferential policies. Numerous advertisements and early launch have made Zocor well-known in community-level hospitals. In an agreement with the Chinese government, MSD promised to lower the prices of Simvastatin for a bigger market share.

This market research shows that the sales value of Simvastatin in sample hospitals in China was about CNY142 million in 2017, and is declining in the competition with other similar drugs. By sales value, China's Simvastatin market is dominated by Hangzhou MSD Pharmaceutical Co., Ltd., MSD, Guangzhou Nanxin Pharmaceutical Co., Ltd., Cinmed Pharmaceuticals, and Yangtze River Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd. In 2017, the market share by sales value of Hangzhou MSD Pharmaceutical Co., Ltd. was about 63%, which means that branded Simvastatin still has great advantages on the Chinese market.

According to this estimate, Simvastatin will still have certain growth potential in China from 2019 to 2023 as the incidences of cardiovascular diseases keep increasing with the rising urbanization level, aging population and changing lifestyle.

Topics Covered:

  •  Development environment of statins in China
  •  Supply of and demand for Simvastatin in China
  •  Major Simvastatin manufacturers in China
  •  Prices of Simvastatin in China
  •  Prospect of China's Simvastatin market from 2019 to 2023
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

1 Relevant Concepts of Simvastatin
1.1 Indications for Simvastatin
1.2 Development of Simvastatin in China
1.3 Governmental Approval of Simvastatin in China

2 Sales of Simvastatin in China, 2013-2017
2.1 Sales Value of Simvastatin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Simvastatin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Simvastatin by Dosage Form in China, 2013-2017
2.3.1 Simvastatin Tablets
2.3.2 Simvastatin Capsules
2.3.3 Simvastatin Pills

3 Analysis of Major Simvastatin Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Simvastatin Manufacturers
1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Hangzhou MSD Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Hangzhou MSD Pharmaceutical Co., Ltd.'s Simvastatin in China
3.3 MSD
3.3.1 Enterprise Profile
3.3.2 Sales of MSD's Simvastatin in China
3.4 Guangzhou Nanxin Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Guangzhou Nanxin Pharmaceutical Co., Ltd.'s Simvastatin in China
3.5 Cinmed Pharmaceuticals
3.6 Yangtze River Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd.

4 Prices of Simvastatin in China, 2017-2018
4.1 Hangzhou MSD Pharmaceutical Co., Ltd. (Zocor)
4.2 MSD (Zocor)
4.3 Guangzhou Nanxin Pharmaceutical Co., Ltd. (Simcor)
4.4 Cinmed Pharmaceuticals (Jianzhiting)
4.5 Yangtze River Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd. (Xindasu)

5 Prospect of China's Simvastatin Market, 2019-2023
5.1 Major Factors Influencing Development China's Simvastatin Market
5.1.1 Favorable Factors
5.1.2 Unfavorable Factors
5.2 Forecast on Market Size of Simvastatin in China
5.3 Forecast on Market Trend of Simvastatin in China

Selected Charts
Chart Government Approval of Simvastatin in China
Chart Sales of Simvastatin in China, 2013-2017
Chart Sales Value of Simvastatin in Parts of China, 2013-2017
Chart Sales Volume of Simvastatin in China, 2013-2017
Chart Sales Volume of Simvastatin in Parts of China, 2013-2017
Chart Sales Value of Simvastatin Tablets in China, 2013-2017
Chart Sales Volume of Simvastatin Tablets in China, 2013-2017
Chart Sales Value of Simvastatin Capsules in China, 2013-2017
Chart Sales Value of Simvastatin Pills in China, 2013-2017
Chart Market Share of Top 5 Simvastatin Manufacturers by Sales Value in China, 2013-2017
Chart Sales Value of Hangzhou MSD Pharmaceutical Co., Ltd.'s Simvastatin, 2013-2017
Chart Sales Volume of Hangzhou MSD Pharmaceutical Co., Ltd.'s Simvastatin, 2013-2017
Chart Profile of MSD
Chart Sales Value of MSD's Simvastatin in China, 2013- 2017
Chart Sales Volume of MSD's Simvastatin in China, 2013- 2017
Chart Profile of Guangzhou Nanxin Pharmaceutical Co., Ltd.
Chart Sales Value of Guangzhou Nanxin Pharmaceutical Co., Ltd.'s Simvastatin, 2013-2017
Chart Prices of Hangzhou MSD Pharmaceutical Co., Ltd.'s Simvastatin (Zocor) in Parts of China, 2017-2018
Chart Prices of MSD's Simvastatin (Zocor) in Parts of China, 2017-2018
Chart Prices of Guangzhou Nanxin Pharmaceutical Co., Ltd.'s Simvastatin (Simcor) in Parts of China, 2017-2018
Chart Prices of Cinmed Pharmaceuticals' Simvastatin (Jianzhiting) in Parts of China, 2017-2018
Chart Forecast on Sales Value of Simvastatin in China, 2019-2023

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Cinmed Pharmaceuticals (Jianzhiting)
  • Guangzhou Nanxin Pharmaceutical Co., Ltd.
  • Hangzhou MSD Pharmaceutical Co., Ltd. (Zocor)
  • MSD
  • Yangtze River Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Adroll
adroll